A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China

Pharmacokinetics Clinical Trial

Official title:

A Study to Assess the Effect of Itraconazole Capsules on the Pharmacokinetics of ZX-7101A Tablets in Healthy Adult Subjects in China

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05949385
• Other study ID #: ZX-7101A-205
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: July 12, 2023
• Est. completion date: February 16, 2024

Study information

• Verified date: June 2023
• Source: Nanjing Zenshine Pharmaceuticals
• Contact: Zhang Jing, Doctor
• Phone: 52887926
• Email: Zhangj_fudan[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to evaluate the effect of Itraconazole on pharmacokinetics of ZX-7101 in healthy Chinese adult subjects after oral administration of ZX-7101A tablets.

The secondary objective of the study is to evaluate the safety and tolerability of single dose of ZX-7101A orally in healthy subjects.

Evaluate the effect of Itraconazole on pharmacokinetics of pre-drug ZX-7101A in healthy Chinese adult subjects after oral administration of ZX-7101A tablets.

Description:

ZX-7101A tablets 40 mg once on Day 1 and Day 31, Itraconazole 200 mg once daily (QD) from Study Day 26 - 50

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 16
• Est. completion date: February 16, 2024
• Est. primary completion date: February 7, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy male or female subjects between the ages of 18 and 45 years (including the threshold value, based on the date of signing ICF).

• Weight: Male weight =50 kg, female weight =45 kg, BMI between 19.0 and 28.0 kg/m2 (including cut-off value), BMI= weight (kg)/height 2 (m2).

• The investigator judged the subjects to be in good overall health based on their medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (routine blood work, urine work, blood biochemistry, coagulation function), viral serology, and chest X-ray results (normal or abnormal test results have no clinical significance).

• Fertile female subjects or male subjects who voluntarily signed ICF should be no fertile, sperm/egg donation for 6 months (female) or 90 days (male) from the beginning to the last dose, and voluntary use highly effective contraception (including partner) (non-drug contraception is required during the trial).

• Fully understand the trial content and possible adverse reactions, have the ability to communicate with researchers normally, while complying with study requirements, follow protocol procedures and restrictions, and be able to visit on time.

Exclusion Criteria:

• Subjects with a prior or present history of clinically abnormal metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disease who were judged by the investigator to be unsuitable for participation in this study.

• Subjects with digestive tract disease or any condition that may affect drug absorption, such as a history of liver and gallbladder disease, gastrointestinal disease, gastrointestinal surgery (except appendectomy) or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.

• Allergic constitutions (such as allergies to two or more drugs, foods, and pollen), or determined by the investigator, may be allergic to the investigational product or any component of the investigational product.

• Acute respiratory infections within 2 weeks before screening; Or have a history of fungal infection.

• For patients with abnormal vital signs (blood pressure, pulse rate, ear temperature) and clinically significant results, the abnormal values of each vital sign are:Body temperature (ear temperature) >37.5 ?; Systolic blood pressure (recumbent) <90 mmHg or =140 mmHg; Diastolic blood pressure (lying) <50 mmHg or =90 mmHg; Pulse rate (lying position) <50 beats/min or >100 beats/min.

• QTcF interval > 450ms or < 300 ms (Fridericia's correction), or QRS>120ms. Abnormal liver function: alanyl aminotransferase (ALT) or aspartate aminotransferase (AST) higher than the upper limit of normal or serum total bilirubin (TBIL) greater than 1.5 times the upper limit of normal, who judged clinical significance by investigators.

• Subjects estimate glomerular filtration rate <90 mL/min/1.73 m2.

• Subjects virus serological test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, treponema pallidum specific antibody TPPA) positive results.

• Subjects with a history of drug abuse (morphine, dimethylene dioxyamphetamine, methamphetamine, THC, ketamine, cocaine) or who screened positive for drug abuse.

• Women who are pregnant or breastfeeding, or who test positive for blood pregnancy.

• Subjects who have used any P-gp or CYP inducer or inhibitor within 30 days before screening, or any prescription or Chinese herbal medicine within 4 weeks before the start of the trial, or over-the-counter or health care products (including polyvalent cations and metal supplements, etc.) within 2 weeks before the start of the trial; It should have a longer time interval if the elimination half-life is longer-at least 5 elimination half-lives for the drug.

• Subjects who consumed more than 14 units of alcohol per week in the 6 months prior before screening (1 unit of alcohol =360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or had a positive alcohol breath test or could not abstain during the trial.

• Subjects who smoked more than 5 cigarettes per day in the 3 months prior before screening or habitually used nicotine-containing products or could not give up during the trial.

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• ZX-7101A
Single dose of oral administration of ZX-7101A and Multiple dose of oral of Itraconazole Capsules

Locations

Country	Name	City	State
China	Huashan Hospital affiliated to Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing Zenshine Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects	Cmax	Day1-Day20, Day31-Day50
Primary	PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects	AUC0-t	Day1-Day20, Day31-Day50
Primary	PK parameters of active metabolite ZX-7101after a single oral ZX-7101A tablet and combined with multiple oral itraconazole capsules in healthy Chinese adult subjects	AUC0-inf	Day1-Day20, Day31-Day50
Secondary	Rate of AE	Rate of TEAE	Day1-Day20, Day31-Day50
Secondary	PK parameters of prodrug ZX-7101A	Cmax	Day1-Day20, Day31-Day50
Secondary	PK parameters of prodrug ZX-7101A	AUC0-t	Day1-Day20, Day31-Day50
Secondary	PK parameters of prodrug ZX-7101A	AUC0-inf	Day1-Day20, Day31-Day50
Secondary	PK parameters of ZX-7101	Tmax	Day1-Day20, Day31-Day50
Secondary	PK parameters of ZX-7101	CL/F	Day1-Day20, Day31-Day50